Please send your CV / resume and any certificates or references as a PDF file by 20th of December 2023 to PD Dr. Ulrich Dischinger at firstname.lastname@example.org.
The central research questions of the project are:
How can the HFpEF phenotype induced in the animal model be influenced by the substances used (especially GLP-1 analogues, SGLT-2 inhibitors) at the level of calcium handling / mitochondrial energetics?
What is the importance of liver function / health (mitochondria, histology, inflammasome) and the different adipose tissue depots?
The aim of this work is to further elucidate the pathophysiological relationships between obesity and heart failure with preserved ejection fraction (with special attention to mitochondrial energy production and calcium balance) and the analysis of drug therapy options in an established animal model (the animal experiment is already approved by the authorities). The topic combines endocrinology and cardiology in an innovative way and provides an excellent basis for further scientific work. It sheds light on established (GLP-1 analogues, SGLT-2 inhibitors) and experimental (PYY) treatment options for obesity. The aim is a comprehensive analysis of the heart by means of highly specific methods (Oroboros, Seahorse) on the one hand and other organs involved in the provision / processing of different energy carriers (liver, adipose tissue depots) on the other. All steps are well established in the participating institutions. The animal experimental approach allows a detailed and comprehensive analysis of cardiac function / energy as well as of a variety of other organs compromised in obesity. Animal experimental experience, which enables in-vivo analysis (e.g. echo), is optional but not a prerequisite.